Navigation Links
Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013
Date:3/11/2013

WINSTON-SALEM, N.C., March 11, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m. EDT to provide a business update and discuss its fourth quarter and full year 2012 financial results. 

To participate in the call, please dial 1-866-543-6403 (domestic) or 1-617-213-8896 (international) and reference access code 98136968. The conference call can be accessed from the Investors & News section of the Company's website or directly at http://www.media-server.com/m/p/pfbbcfmc.

A replay of the call will be available one hour after the end of the conference on March 18, 2013 until 11:59 p.m. EDT on March 25, 2013. To access the replay, please dial 1-888-286-8010 (domestic) or 1-617-801-6888 (international) and reference the access code 69683056. The archived webcast will be available for 30 days on the Company's website at www.tengion.com.

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

 

 

 


'/>"/>
SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Provides Business Update and Reports Third Quarter 2012 Financial Results
2. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
3. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
4. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
5. ISPE Conference to Benchmark and Advance Quality by Design in the Biopharmaceutical Industry
6. Discovery Labs to Report Fourth Quarter 2012 Results and Hold Conference Call on Wednesday, March 13, 2013
7. Registration Now Open for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego
8. Fourth Annual Bay Area Biomedical Device Conference: March 27th, 2013 at San Jose State University
9. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
10. AVANIR Pharmaceuticals To participate in two conferences in March
11. Lexicon To Present At The Cowen Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which ... today to pursue the highest level of accuracy and quality with the addition ... and the AR5 Refractometer. Accurate, reliable and tough enough for the most ...
(Date:2/10/2016)... BioAmber Inc. (NYSE: BIOA ), a leader in ... Co. Ltd., its partner in the Sarnia ... additional CDN$25 million in the joint venture for 10% ... 40%.  Mitsui will also play a stronger role in ... Sarnia , providing dedicated resources alongside BioAmber,s commercial ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
Breaking Biology Technology:
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):